These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10086326

  • 1. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Discafani CM, Carroll ML, Floyd MB, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Minnick AA, Nilakantan R, Shen R, Wang YF, Wissner A, Greenberger LM.
    Biochem Pharmacol; 1999 Apr 15; 57(8):917-25. PubMed ID: 10086326
    [Abstract] [Full Text] [Related]

  • 2. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
    Wissner A, Berger DM, Boschelli DH, Floyd MB, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou HR, Upeslacis E, Wang YF, Wu B, Ye F, Zhang N.
    J Med Chem; 2000 Aug 24; 43(17):3244-56. PubMed ID: 10966743
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA.
    J Med Chem; 2000 Apr 06; 43(7):1380-97. PubMed ID: 10753475
    [Abstract] [Full Text] [Related]

  • 4. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
    Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A.
    J Med Chem; 2001 Aug 16; 44(17):2719-34. PubMed ID: 11495584
    [Abstract] [Full Text] [Related]

  • 5. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.
    Mol Cancer Ther; 2001 Dec 16; 1(2):85-94. PubMed ID: 12467226
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
    Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA.
    J Med Chem; 2001 Feb 01; 44(3):429-40. PubMed ID: 11462982
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.
    J Med Chem; 1998 Feb 26; 41(5):742-51. PubMed ID: 9513602
    [Abstract] [Full Text] [Related]

  • 8. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
    Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM.
    Proc Natl Acad Sci U S A; 1998 Sep 29; 95(20):12022-7. PubMed ID: 9751783
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
    Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, Leopold WR.
    Invest New Drugs; 1996 Sep 29; 13(4):295-302. PubMed ID: 8824347
    [Abstract] [Full Text] [Related]

  • 10. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
    Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR.
    Breast Cancer Res Treat; 1996 Sep 29; 38(1):67-73. PubMed ID: 8825124
    [Abstract] [Full Text] [Related]

  • 11. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
    Cassinelli G, Lanzi C, Pensa T, Gambetta RA, Nasini G, Cuccuru G, Cassinis M, Pratesi G, Polizzi D, Tortoreto M, Zunino F.
    Biochem Pharmacol; 2000 Jun 15; 59(12):1539-47. PubMed ID: 10799650
    [Abstract] [Full Text] [Related]

  • 12. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.
    Cancer Chemother Pharmacol; 2000 Jun 15; 45(3):231-8. PubMed ID: 10663641
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.
    J Med Chem; 1999 May 20; 42(10):1803-15. PubMed ID: 10346932
    [Abstract] [Full Text] [Related]

  • 14. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.
    J Med Chem; 1997 Oct 24; 40(22):3601-16. PubMed ID: 9357527
    [Abstract] [Full Text] [Related]

  • 15. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Pharm Belg; 1997 Oct 24; 52(2):88-96. PubMed ID: 9193132
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM, Murray DK, Elliott WL, Fry DW, Nelson JA, Showalter HD, Roberts BJ, Vincent PW, Denny WA.
    J Med Chem; 1997 Nov 21; 40(24):3915-25. PubMed ID: 9397172
    [Abstract] [Full Text] [Related]

  • 17. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
    Gaul MD, Guo Y, Affleck K, Cockerill GS, Gilmer TM, Griffin RJ, Guntrip S, Keith BR, Knight WB, Mullin RJ, Murray DM, Rusnak DW, Smith K, Tadepalli S, Wood ER, Lackey K.
    Bioorg Med Chem Lett; 2003 Feb 24; 13(4):637-40. PubMed ID: 12639547
    [Abstract] [Full Text] [Related]

  • 18. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Med Chem; 1996 Jun 07; 39(12):2285-92. PubMed ID: 8691423
    [Abstract] [Full Text] [Related]

  • 19. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.
    Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI.
    Int J Cancer; 1997 Jun 11; 71(6):1010-8. PubMed ID: 9185705
    [Abstract] [Full Text] [Related]

  • 20. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
    Cockerill S, Stubberfield C, Stables J, Carter M, Guntrip S, Smith K, McKeown S, Shaw R, Topley P, Thomsen L, Affleck K, Jowett A, Hayes D, Willson M, Woollard P, Spalding D.
    Bioorg Med Chem Lett; 2001 Jun 04; 11(11):1401-5. PubMed ID: 11378364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.